US 11,885,817 B2
Biomarkers and methods for detection of seizures and epilepsy
Todd Wallach, Overland Park, KS (US); Elisa A. Waxman, Overland Park, KS (US); John Gledhill, Overland Park, KS (US); Richard St. Clair, Overland Park, KS (US); and Elizabeth Brand, Overland Park, KS (US)
Assigned to Cognizance Biomarkers, LLC, Miami, FL (US)
Appl. No. 16/613,968
Filed by EVOGEN, INC., Overland Park, KS (US)
PCT Filed May 16, 2018, PCT No. PCT/US2018/032956
§ 371(c)(1), (2) Date Nov. 15, 2019,
PCT Pub. No. WO2018/213437, PCT Pub. Date Nov. 22, 2018.
Claims priority of provisional application 62/506,878, filed on May 16, 2017.
Prior Publication US 2022/0178948 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); C07K 16/24 (2006.01); G16H 10/60 (2018.01); G16H 50/70 (2018.01); G16H 50/20 (2018.01)
CPC G01N 33/6896 (2013.01) [C07K 16/244 (2013.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G01N 2333/521 (2013.01); G01N 2333/525 (2013.01); G01N 2333/5446 (2013.01); G01N 2800/2857 (2013.01); G01N 2800/52 (2013.01); G16H 10/60 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01)] 11 Claims
 
1. A method of treating epilepsy in a patient in need of epilepsy treatment, the method comprising:
contacting one or more blood samples obtained from the patient with one or more antibodies targeting one or more biomarkers selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin (IL)-7, monocyte chemotactic protein (MCP)-4, macrophage colony-stimulating factor (M-CSF), MCP-2, IL-8, macrophage inflammatory protein (MIP)-1B, macrophage migration inhibitory factor (MIF), Eotaxin, MIP-5, IL-15, Eotaxin-2, TNF-RI, interferon gamma-induced protein 10 (IP-10), granulocyte macrophage colony stimulating factor (GM-CSF), IL-12p70, and IL-1B;
measuring the concentrations of the one or more biomarkers in the one or more blood samples;
comparing the concentrations of the one or more biomarkers in the one or more blood samples to the concentration of the one or more biomarkers in one or more controls; and
treating the patient for epilepsy by administering to the patient one or more therapeutic agents selected from the group consisting of phenytoin, carbamazepine, oxcarbazepine, zonisamide, lamotrigine, and pharmaceutically acceptable salts and prodrugs thereof;
wherein the patient is in need of epilepsy treatment when the concentrations of the one or more biomarkers are elevated in the one or more blood samples relative to the one or more controls.